Glenmark Pharmaceuticals Limited FII & DII Activity
5-Day Flow Trend
| Date | FII Net (₹ Cr) | DII Net (₹ Cr) |
|---|---|---|
| 2026-09-04 | −3111.94 | +8930.12 |
| 2026-09-03 | −2345.87 | +4977.46 |
| 2026-09-02 | +6688.37 | +2812.98 |
| 2026-09-01 | −7985.88 | +4588.88 |
| 2026-08-31 | −7985.88 | +4588.88 |
Today's Institutional Flow
On 4 September 2026, foreign institutional investors (FIIs) recorded a net cash outflow of ₹‑3,111.94 Cr, while domestic institutional investors (DIIs) posted a net cash inflow of ₹ 8,930.12 Cr. The contrasting directions underscore a strengthening domestic appetite amid a withdrawal of foreign capital. Overall, the market‑wide cash flows suggest a net inflow of roughly ₹ 5,818 Cr for the day, driven primarily by the sizeable DII participation.
Trend vs 5‑Day Average
The day's FII cash outflow of ₹‑3,111.94 Cr is milder than the five‑day average outflow of ₹‑3,333.81 Cr, indicating a slight easing of foreign sell pressure. Conversely, the DII cash inflow of ₹ 8,930.12 Cr exceeds the five‑day average of ₹ 4,430.43 Cr, reflecting a pronounced and persistent domestic buying bias over the recent period.
F&O Positioning Data
FIIs added a net ₹ 374,795 Cr to futures‑and‑options (F&O) contracts, signalling continued speculative or hedging activity in derivatives. Their index‑futures stance shows a long‑to‑short ratio of 1.2, meaning long positions modestly outnumber short positions.
Healthcare Sector Flow
The broader healthcare sector, to which Glenmark Pharmaceuticals belongs, has experienced a recent tilt toward DII buying and modest FII selling, reinforcing a domestic‑driven bullish tilt in the segment.
Market-wide FII/DII data — same for all F&O stocks. Date: 2026-09-04